Toppo M, Gour D, Lodha RS, Kamble M, Keerthana S. A Case-Control Study on Mucormycosis in Tertiary Care Hospital, Bhopal.
Indian J Community Med 2022;
47:396-399. [PMID:
36438517 PMCID:
PMC9693956 DOI:
10.4103/ijcm.ijcm_1320_21]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2021] [Revised: 02/17/2022] [Accepted: 03/26/2022] [Indexed: 06/16/2023] Open
Abstract
BACKGROUND
The term mucormycosis refers to any fungal infection caused by fungi belonging to the Mucorales order. The disease often manifests in the skin and also affects the lungs and the brain. A large number of Mucormycosis cases were detected in Delhi, Maharashtra and Gujarat, and Madhya Pradesh.
OBJECTIVES
(1) To describe the epidemiology, management, and outcome of individuals with mucormycosis. (2) To evaluate the risk factors associated with cases and control.
METHODOLOGY
A case-control study, conducted in Hamidia Hospital, Bhopal, for 5 weeks. One hundred and sixty-eight patients diagnosed clinically with radiological or pathological findings was considered a case of Mucormycosis. Control was taken from March 2020 to May 28, 2021, the list of COVID-19-positive patients obtained from IDSP, MP.
RESULTS
Majority of the study participants were among the age group of 51-60 years and comprising 69.6% of males. Diabetes mellitus is the major comorbidity found in both cases (87.58%) and in controls (20.0%).
CONCLUSION
There is a need to stress to control hyperglycemia, and monitor blood glucose levels after discharge following COVID-19 treatment.
Collapse